FDG-PET findings associated with various medical procedures and treatments

Jpn J Radiol. 2023 May;41(5):459-476. doi: 10.1007/s11604-022-01376-w. Epub 2022 Dec 28.

Abstract

[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well-established modality with high sensitivity for the diagnosis and staging of oncologic patients. FDG is taken up by the glucose transporter of the cell membrane and becomes trapped within the cell. In addition to malignant neoplasms, active inflammatory lesions and some kinds of benign tumors also accumulate FDG. Moreover, the degree of uptake into normal organs and tissues depends on various physiological conditions, which is affected by various medical procedures, treatments, and drugs. To avoid misleading interpretations, it is important to recognize possible situations of unexpected abnormal accumulation that mimic tumor lesions. In this review, we present various FDG findings associated with surgical or medical procedures and treatments. Some findings reflect the expected physiological reaction to treatment, and some show inflammation due to prior procedures. Occasionally, FDG-PET visualizes other disorders that are unrelated to the malignancy, which may be associated with the adverse effects of certain drugs that the patient is taking. Careful review of medical records and detailed interviews of patients are thus necessary.

Keywords: Adverse effect; FDG–PET; Medical procedures; Physiological effect; Physiological reaction.

Publication types

  • Review

MeSH terms

  • Fluorodeoxyglucose F18*
  • Humans
  • Inflammation / diagnostic imaging
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals*

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals